当前位置： SCI文献检索 > CLINICAL NUCLEAR MEDICINE期刊下所有文献 > FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer.

FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer.

Abstract：

BACKGROUND:We aim to retrospectively evaluate the impact of hormone therapy (HT) on FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT. PATIENTS AND METHODS:Three hundred eight patients with BC were scanned with PET/CT at 2 Italian institutions (mean time from diagnosis 4 yrs, range: 1-24 yrs). Main indications for PET/CT were elevation of tumor markers (34.4%) and clinical or radiological suspicion of relapse (65.6%). The diagnostic accuracy of FDG PET/CT was computed according to the standard method. Student t test was used to assess the mean differences between the study groups, whereas categorical data were compared with chi-square test. Significance was set at P <0.05. RESULTS:Two hundred sixty-four patients with positive estrogen receptor and who had received adjuvant HT were included in the analysis. At the time of PET/CT scan, HT was ongoing in 176 patients (66.7%) and 88 (33.3%) had completed adjuvant HT. Ninety-eight (55.7%) patients on HT and 59 (67%) off HT had a positive PET/CT; therefore, the scan resulted negative in the remaining 107 patients, 78 and 29 on and off HT, 44.3% and 33%, respectively (P < 0.001). At a median follow-up of 7 months (range 1-48 mos), disease recurrence was confirmed in either clinical or radiological examinations in 126 (47.7%) patients; 72 (40.9%) versus 54 (61.4%) patients on and off HT, respectively (P < 0.005). True-positive PET/CT results were found in 82% and 91% of patients on and off HT, respectively, whereas it failed to identify disease relapse in 13 (18%) and 5 (9%) patients on and off HT, respectively. CONCLUSIONS:In our series, FDG PET/CT shows a similar diagnostic accuracy in detecting disease relapse between patients with BC on adjuvant HT versus those who have completed therapy. These preliminary results suggest that the glucose metabolism is not altered by hormonal suppression at the time of the scan.

journal_name

Clin Nucl Med

journal_title

Clinical nuclear medicine

authors

Evangelista L,Redana S,Racca M,Geuna E,Vinante L,Zago G,De Carolis V,Ghiotto C,Saladini G,Varetto T

doi

10.1097/RLU.0b013e318287353e

subject

Has Abstract

pub_date

2014-02-01 00:00:00

pages

e135-41

issue

eissn

0363-9762

issn

1536-0229

pii

00003072-201402000-00033

journal_volume

pub_type

杂志文章

在线工具

FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer.